1. Lamivudine + INF - a At each visit: clinical examination, transaminase
TW0
TW1
TW2
TW4
TW6
TW8/9
TW12
TW16
TW20
TW24
TW28
TW32
TW36
TW40
TW44
TW48
TW52
FUW4
FUW12
FUW24
FUW52
FUW104
FUW156
At each visit: clinical examination,
transaminase
and amylase levels, FBC
HBV-DNA, HBV serology,
HBsAg
level, genotyping, YMDD
Lamivudine
+ INF - a
HBV-DNA,
HBV serology,
level
level,
YMDD
Follow
up:
Liver
Plasma
Figure 1 1

2. Responders Non-responders B A C D Figures 2
Plasma HBV-DNA [log10 IU/ml]
Figures 2
Responders
Non-responders
p=0.04
p=0.01
p<0.01
p=0.05 -9 -8 -7 -6 -5 -4 -3 -2 -1
TW0
TW2
TW9
TW28
TW52
FUW24
FUW52
Difference HBV-DNA [log10 IU/ml] B A C D
Untreated

3. Responders Non-responders A B D C Responders Non-responders Figures 3
Plasma HBsAg [log10 IU/ml]
Plasma HBsAg [log10 IU/ml]
p<0.01
p<0.01 D
Untreated C
p=0.02
Plasma HBsAg [log10 IU/ml]
p<0.01
p<0.01
p<0.01
Responders
Non-responders

4. Decline > 1 < 2 log10IU/ml Decline > 0.5 < 1 log10IU/ml
Figures 4 A
Decline > 2 log10IU/ml B
Decline > 1 < 2 log10IU/ml C
Decline > 0.5 < 1 log10IU/ml D
Decline < 0.5 log10IU/ml
Responders
Non-responders

5. Responders Non-responders A B C D E Figures 5 r=0.46 p=0.03 r=0.6
TW0 B
TW9 C
TW28 D
TW52 E
FUW24
Responders
Non-responders